Figure 1. c-Myc inhibition restrains aberrant CAR-T cell differentiation ex vivo.

T cells were activated with anti-CD3/anti-CD28 and transduced with CD33 CAR or empty vector. Five days after initial activation, CD33 CAR-T cells were treated with c-Myc inhibitors JQ-1 or iBET as indicated for four days. Percentages of T_N (naïve; CCR7⁺CD45RA⁺), T_CM (central memory; CCR7⁺CD45RA^–), T_EM (effector memory; CCR7^–CD45RA^–) and T_EFF (effector; CCR7^–CD45RA⁺) subsets of CD8⁺ T cells were determined by flow cytometry. Results indicate that the bromodomain inhibitors increase the proportion of longer-lived naïve and central memory phenotype T cells.